Pierce James Andrew, Group President at Stryker Corporation (SYK), has demonstrated a clear selling bias in his recent insider transactions, with $14.1 million in total sales outweighing $3.0 million in purchases across 24 filings since early 2024. His activity has been concentrated almost exclusively in SYK shares, with only a single non-executed award filing for Envista Holdings (NVST) in July 2025. The most recent trade, a $2.62 million sale on March 21, 2026, follows a pattern of substantial dispositions, including a $1.75 million sale on February 2, 2026, and multiple seven-figure transactions throughout 2025 and early 2026. These sales frequently coincide with the vesting of awards (coded "M") and option exercises (coded "F"), such as the $3.1 million option exercise paired with a $1.3 million same-day sale on February 2, 2026.
Andrew's trading rhythm appears tied to scheduled corporate events, with multiple March transactions—including a $2.5 million option exercise on March 21, 2025—suggesting an annual pattern. While the filings show routine award grants (coded "A" and "G") with no reported value, his monetization of equity compensation is consistent. The absence of open-market purchases since at least 2024, coupled with the systematic liquidation of vested shares, presents a one-sided transactional profile. This activity spans both bull and bear markets in medical device stocks, indicating a disposition strategy decoupled from short-term market conditions.
AI-assisted summary